Furthermore, the new insights on the pathogenesis and therapy of AD also indicated the adaptive immune response contributing to the deposition of Aβ in the brain and misfolded tau proteins (Ashraf et al., 2018; Uddin et al., 2020b), which might open new perspectives in the treatments for AD with active and passive anti-Aβ immunotherapies clearing brain Aβ deposits (Ciccocioppo et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.